Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. (Q53750044)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

1 reference

based on heuristic

inferred from title

prostate adenocarcinoma

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Alessandro Sgambato

5

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

9

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

10

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Ettore Novellino

16

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Alfredo Budillon

18

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Michele Caraglia

19

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Giuseppina Bozzuto

object named as

Giuseppina Bozzuto

3

0 references

Agnese Molinari

object named as

Agnese Molinari

17

0 references

object named as

Mario Migaldi

8

0 references

15

object named as

Gerardo Botti

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

author name string

Paolo Grieco

1

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Laura Toccacieli

4

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Monica Marra

6

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Silvia Zappavigna

7

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Stefano Striano

11

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Luigi Marra

12

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Luigi Gallo

13

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Achille Cittadini

14

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

publication date

1 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

Journal of Cellular Biochemistry

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

112

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

1

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

341-353

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

20-year outcomes following conservative management of clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Effect of endothelin-1 as growth factor on a human glioma cell line; its characteristic promotion of DNA synthesis

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Urotensin-II receptor peptide agonists

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Genomic analysis of metastasis reveals an essential role for RhoC

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

The focal adhesion kinase--a regulator of cell migration and invasion

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Treatment decisions for localized prostate cancer: asking men what's important

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Differential regulation of cell motility and invasion by FAK

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

MMP inhibition in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Spatiotemporal dynamics of RhoA activity in migrating cells

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Molecular markers of prostate cancer outcome

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Expression of endothelin-1 and endothelin receptors in cultured human glioblastoma cells

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Architecture of the Human Urotensin II Receptor: Comparison of the Binding Domains of Peptide and Non-Peptide Urotensin II Agonists

1 reference

https://api.crossref.org/works/10.1002%2FJCB.22933

21 January 2018

Identifiers

10.1002/JCB.22933

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/21080343

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53750044&oldid=1505439816"